Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 87 for:    TAKE-IT
Previous Study | Return to List | Next Study

Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2017 by Northwestern University
Sponsor:
Collaborators:
Mayo Clinic
Northwestern Memorial Hospital
University of Illinois at Chicago
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT03104868
First received: March 28, 2017
Last updated: April 1, 2017
Last verified: April 2017
  Purpose
The investigators will evaluate a technology-enabled strategy designed to promote medication adherence, routinely monitor regimen use, and mobilize appropriate transplant center resources to respond early to kidney transplant recipients demonstrating inadequate adherence.

Condition Intervention
Kidney Transplant
Behavioral: TAKE IT Strategy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Participants will be randomized to one of two arms: TAKE IT strategy or usual care.
Masking: Participant, Investigator
Masking Description:
We will blind: 1) research interviewers involved with outcomes assessment, 2) personnel involved in statistical analyses (Dr. Kwasny, Ms. Patel), 3) principal investigators (Wolf, Ladner). Site project managers will have access to study arm assignments to initiate TAKE IT components to those randomized to receive them.
Primary Purpose: Supportive Care
Official Title: Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Rx regimen adherence score using the Patient Medication Adherence Questionnaire (PMAQ) [ Time Frame: 2 years ]
    A subjective measurement of missed medication doses


Secondary Outcome Measures:
  • Correct dosing (per med) [ Time Frame: 2 years ]
    Properly demonstrating correct dose (# of pills), spacing (hours between doses), frequency (times per day), and total pills per day.

  • Change in eGFR (estimated glomurular filtration rate), ml/mm [ Time Frame: 2 years ]
    Change in eGFR rate over 2 years

  • Re-hospitalization [ Time Frame: 2 years ]
    Acute care hospitalizations post transplant


Estimated Enrollment: 700
Anticipated Study Start Date: October 2017
Estimated Study Completion Date: April 2022
Estimated Primary Completion Date: January 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Usual Care
Patients in this group will receive the usual standard of care.
Experimental: Intervention
Patients in this group will receive the TAKE IT strategy components.
Behavioral: TAKE IT Strategy

The TAKE IT Strategy includes:

  1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.
  2. SMS text-messaging to remind patients when to take all their medicine.
  3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.
  4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1) age 18 or older
  • 2) within 3 months of KT (de novo) or 18-36 months post-KT (established)
  • 3) English speaking
  • 4) primarily responsible for administering own medication
  • 5) own a cell phone and comfortable receiving text messages
  • 6) access and proficiency using internet in home.

Exclusion Criteria:

  • any severe, uncorrectable vision, hearing or cognitive impairments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03104868

Contacts
Contact: Michael S Wolf, PhD 312-503-5592 mswolf@northwestern.edu

Sponsors and Collaborators
Northwestern University
Mayo Clinic
Northwestern Memorial Hospital
University of Illinois at Chicago
  More Information

Responsible Party: Northwestern University
ClinicalTrials.gov Identifier: NCT03104868     History of Changes
Other Study ID Numbers: STU00204465
Study First Received: March 28, 2017
Last Updated: April 1, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

ClinicalTrials.gov processed this record on May 22, 2017